|
1
|
Weston CR and Davis RJ: The JNK signal
transduction pathway. Curr Opin Cell Biol. 19:142–149. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kennedy NJ and Davis RJ: Role of JNK in
tumor development. Cell Cycle. 2:199–201. 2003.PubMed/NCBI
|
|
3
|
Wagner EF and Nebreda AR: Signal
integration by JNK and p38 MAPK pathways in cancer development. Nat
Rev Cancer. 9:537–549. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen F: JNK-induced apoptosis,
compensatory growth, and cancer stem cells. Cancer Res. 72:379–386.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kitanaka C, Sato A and Okada M: JNK
signaling in the control of the tumor-initiating capacity
associated with cancer stem cells. Genes Cancer. January
22–2013.(Epub ahead of print). View Article : Google Scholar
|
|
6
|
Matsuda K, Sato A, Okada M, et al:
Targeting JNK for therapeutic depletion of stem-like glioblastoma
cells. Sci Rep. 2:5162012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yoon CH, Kim MJ, Kim RK, et al: c-Jun
N-terminal kinase has a pivotal role in the maintenance of
self-renewal and tumorigenicity in glioma stem-like cells.
Oncogene. 31:4655–4666. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yu Y, Ramena G and Elble RC: The role of
cancer stem cells in relapse of solid tumors. Front Biosci.
4:1528–1541. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Malik B and Nie D: Cancer stem cells and
resistance to chemo and radio therapy. Front Biosci. 4:2142–2149.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
11
|
Collins LG, Haines C, Perkel R and Enck
RE: Lung cancer: diagnosis and management. Am Fam Physician.
75:56–63. 2007.
|
|
12
|
Li JY, Wang H, May S, et al: Constitutive
activation of c-Jun N-terminal kinase correlates with histologic
grade and EGFR expression in diffuse gliomas. J Neurooncol.
88:11–17. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Antonyak MA, Kenyon LC, Godwin AK, et al:
Elevated JNK activation contributes to the pathogenesis of human
brain tumors. Oncogene. 21:5038–5046. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tsuiki H, Tnani M, Okamoto I, et al:
Constitutively active forms of c-Jun NH2-terminal kinase
are expressed in primary glial tumors. Cancer Res. 63:250–255.
2003.PubMed/NCBI
|
|
15
|
Cui J, Han SY, Wang C, et al: c-Jun
NH2-terminal kinase 2α2 promotes the tumorigenicity of
human glioblastoma cells. Cancer Res. 66:10024–10031. 2006.
|
|
16
|
Khatlani TS, Wislez M, Sun M, et al: c-Jun
N-terminal kinase is activated in non-small-cell lung cancer and
promotes neoplastic transformation in human bronchial epithelial
cells. Oncogene. 26:2658–2666. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nitta RT, Del Vecchio CA, Chu AH, Mitra
SS, Godwin AK and Wong AJ: The role of the c-Jun N-terminal kinase
2-α-isoform in non-small cell lung carcinoma tumorigenesis.
Oncogene. 30:234–244. 2011.
|
|
18
|
Lee JJ, Lee JH, Ko YG, Hong SI and Lee JS:
Prevention of premature senescence requires JNK regulation of Bcl-2
and reactive oxygen species. Oncogene. 29:561–575. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Perez EA, Hack FM, Fletcher TS and Chou
TC: Modulation of intrinsic in vitro resistance to carboplatin by
edatrexate in the A549 human nonsmall cell lung cancer cell line.
Oncol Res. 6:151–156. 1994.PubMed/NCBI
|
|
20
|
Eramo A, Ricci-Vitiani L, Zeuner A, et al:
Chemotherapy resistance of glioblastoma stem cells. Cell Death
Differ. 13:1238–1241. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Eramo A, Lotti F, Sette G, et al:
Identification and expansion of the tumorigenic lung cancer stem
cell population. Cell Death Differ. 15:504–514. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
et al: Identification and expansion of human colon
cancer-initiating cells. Nature. 445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sato A, Sunayama J, Okada M, et al:
Glioma-initiating cell elimination by metformin activation of FOXO3
via AMPK. Stem Cells Transl Med. 1:811–824. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bennett BL, Sasaki DT, Murray BW, et al:
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase.
Proc Natl Acad Sci USA. 98:13681–13686. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xia Z, Dickens M, Raingeaud J, Davis RJ
and Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases
on apoptosis. Science. 270:1326–1331. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dhanasekaran DN and Reddy EP: JNK
signaling in apoptosis. Oncogene. 27:6245–6251. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Verheij M, Ruiter GA, Zerp SF, et al: The
role of the stress-activated protein kinase (SAPK/JNK) signaling
pathway in radiation-induced apoptosis. Radiother Oncol.
47:225–232. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fan M and Chambers TC: Role of
mitogen-activated protein kinases in the response of tumor cells to
chemotherapy. Drug Resist Updat. 4:253–267. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cellurale C, Sabio G, Kennedy NJ, et al:
Requirement of c-Jun NH2-terminal kinase for
Ras-initiated tumor formation. Mol Cell Biol. 31:1565–1576.
2011.PubMed/NCBI
|
|
30
|
Jackson EL, Willis N, Mercer K, et al:
Analysis of lung tumor initiation and progression using conditional
expression of oncogenic K-ras. Genes Dev. 15:3243–3248.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vachtenheim J: Occurrence of ras mutations
in human lung cancer. Minireview Neoplasma. 44:145–149.
1997.PubMed/NCBI
|
|
32
|
Kadara H, Kabbout M and Wistuba II:
Pulmonary adenocarcinoma: a renewed entity in 2011. Respirology.
17:50–65. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kurtze I, Sonnemann J and Beck JF:
KRAS-mutated non-small cell lung cancer cells are responsive to
either co-treatment with erlotinib or gefitinib and histone
deacetylase inhibitors or single treatment with lapatinib. Oncol
Rep. 25:1021–1029. 2011.PubMed/NCBI
|
|
34
|
Okudela K, Hayashi H, Ito T, et al: K-ras
gene mutation enhances motility of immortalized airway cells and
lung adenocarcinoma cells via Akt activation: possible contribution
to non-invasive expansion of lung adenocarcinoma. Am J Pathol.
164:91–100. 2004. View Article : Google Scholar
|
